Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

doi:10.20892/j.issn.2095-3941.2017.0054

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
	Zhang, Meng 1,3; Liu, Ergang 3,4; Cui, Yanna 2,3; Huang, Yongzhuo1,3
刊名	CANCER BIOLOGY & MEDICINE
	2017-08
卷号	14 期号:3 页码:212-227
ISSN号	2095-3941
DOI	10.20892/j.issn.2095-3941.2017.0054
文献子类	Review
英文摘要	Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.
资助项目	National Basic Research Program of China[973 Program 2014CB931900] ; National Basic Research Program of China[2013CB932503] ; National Natural Science Foundation of China[81373357] ; National Natural Science Foundation of China[81422048] ; National Natural Science Foundation of China[81673382] ; National Natural Science Foundation of China[81521005]
WOS关键词	CHEMO-PHOTOTHERMAL THERAPY ; DRUG-DELIVERY SYSTEM ; TARGETED CO-DELIVERY ; GLYCOPROTEIN MEDIATED EFFLUX ; BREAST-CANCER ; P-GLYCOPROTEIN ; IN-VITRO ; SILICA NANOPARTICLES ; OVARIAN-CANCER ; SURVIVORSHIP STATISTICS
WOS研究方向	Oncology ; Research & Experimental Medicine
语种	英语
CSCD记录号	CSCD:6066839
出版者	CHINESE ANTI-CANCER ASSOC
WOS记录号	WOS:000417395100002
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/272534]
专题	药物制剂研究中心
通讯作者	Huang, Yongzhuo
作者单位	1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China; 2.Chinese Acad Sci, Inst Neurosci, Key Lab Primate Neurobiol, Shanghai 200031, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; 4.Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China;
推荐引用方式 GB/T 7714	Zhang, Meng,Liu, Ergang,Cui, Yanna,et al. Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer[J]. CANCER BIOLOGY & MEDICINE,2017,14(3):212-227.
APA	Zhang, Meng,Liu, Ergang,Cui, Yanna,&Huang, Yongzhuo.(2017).Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.CANCER BIOLOGY & MEDICINE,14(3),212-227.
MLA	Zhang, Meng,et al."Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer".CANCER BIOLOGY & MEDICINE 14.3(2017):212-227.